Notice of Proposed Sale · 144
Sight Sciences, Inc.
SGHTNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Sight Sciences, Inc.
- Issuer CIK
- 0001531177
- SEC file number
- 001-40587
- Phone
- (415) 889-0550
- Person for whose account securities are to be sold
- Taylor Brenton
- Relationships to issuer
- Officer
- Street
- 4040 CAMPBELL AVE,
- Street (continued)
- SUITE 100
- City
- MENLO PARK
- State / country code
- CA
- Postal code
- 94025
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 2,988 | 26,453.37 | 55,087,990 | 10/02/2026 | NASDAQ | Fidelity Brokerage Services LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- Fidelity Brokerage Services LLC
- Street
- 900 Salem Street
- City
- Smithfield
- State / country code
- RI
- Postal code
- 02917
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 09/30/2026 | Restricted Stock Vesting | Issuer | 2,988 | N | 09/30/2026 | Compensation |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Notice signature
- Notice date
- 10/02/2026
- Signed
- /s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Brenton Taylor
Company context
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System and OMNI® Edge Surgical System are implant-free, minimally invasive glaucoma surgery technologies indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical System is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information.